Hyperkalemia: A Cause of Non-adherence to Renin- Angiotensin-Aldosterone System Inhibitors in Chronic Kidney Disease: A Retrospective Study

Introduction: There is increasing awareness of non-adherence to renin-angiotensin- aldosterone system inhibitors (RAASi) in chronic kidney disease (CKD). This study aimed to evaluate the incidence of hyperkalemic adult CKD patients who were prescribed RAASi and to determine variations in pharmacolog...

Full description

Bibliographic Details
Main Authors: Sibel Gülçiçek, Nurhan Seyahi
Format: Article
Language:English
Published: Galenos Yayinevi 2023-11-01
Series:İstanbul Medical Journal
Subjects:
Online Access: http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/hyperkalemia-a-cause-of-non-adherence-to-renin--an/63650
_version_ 1827629771764269056
author Sibel Gülçiçek
Nurhan Seyahi
author_facet Sibel Gülçiçek
Nurhan Seyahi
author_sort Sibel Gülçiçek
collection DOAJ
description Introduction: There is increasing awareness of non-adherence to renin-angiotensin- aldosterone system inhibitors (RAASi) in chronic kidney disease (CKD). This study aimed to evaluate the incidence of hyperkalemic adult CKD patients who were prescribed RAASi and to determine variations in pharmacological interventions to uncover reasons for non-adherence to RAASi treatment. Methods: The incidence of hyperkalemia and non-adherence to RAASi [angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blockers (ARBs)] in CKD patients was examined among 471 patients over the age of 18 years who had estimated-glomerular filtration rate (e-GFR) measurements and were diagnosed with CKD between stages 1 and 5. Hyperkalemia was defined as serum potassium (K+) ≥5 mmol/L. The number of hyperkalemic patients not reaching the target dose, hyperkalemia as a reason for not reaching the target dose, patients receiving sodium polystyrene sulfonate patients discontinuing ACEi/ARBs, having a decreased dose of ACEi/ARBs, or treated with the addition or increasing dose of diuretics were compared between the hyperkalemia groups. Results: Hyperkalemia was detected in 29.1% of the patients (n=137), being mild in 21.7%, moderate in 6.2%, and severe in 1.3%. The main finding was that the frequency of patients not reaching the target dose of ACEi/ARBs treatment due to hyperkalemia, hypotension, or e-GFR increase higher than 30% was dramatically higher among patients having moderate/severe hyperkalemia (p<0.0001). In 12.41% of hyperkalemic patients, hyperkalemia was cited as the cause for not achieving the target dosage of ACEi/ARB therapy. 25.71% of these patients discontinued ACEi/ARBS treatment, 14.29% had decreased dose of this treatment, and 11.43% had increased dose of diuretics or newly prescribed diuretics. However, none of the patients with mild hyperkalemia experienced these events during treatment. Conclusion: These findings suggest that serum K+ concentration may be related to major adverse clinical outcomes and affect the type of pharmacological intervention in CKD, resulting in ACEi-ARB discontinuation and halting to reach the target dose.
first_indexed 2024-03-09T13:57:07Z
format Article
id doaj.art-7d809e8c8e4a4e259c0def0a000fac2c
institution Directory Open Access Journal
issn 2619-9793
2148-094X
language English
last_indexed 2024-03-09T13:57:07Z
publishDate 2023-11-01
publisher Galenos Yayinevi
record_format Article
series İstanbul Medical Journal
spelling doaj.art-7d809e8c8e4a4e259c0def0a000fac2c2023-11-30T12:44:53ZengGalenos Yayineviİstanbul Medical Journal2619-97932148-094X2023-11-0124440441110.4274/imj.galenos.2023.5588913049054Hyperkalemia: A Cause of Non-adherence to Renin- Angiotensin-Aldosterone System Inhibitors in Chronic Kidney Disease: A Retrospective StudySibel Gülçiçek0Nurhan Seyahi1 University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Nephrology, İstanbul, Turkey İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Nephrology, İstanbul, Turkey Introduction: There is increasing awareness of non-adherence to renin-angiotensin- aldosterone system inhibitors (RAASi) in chronic kidney disease (CKD). This study aimed to evaluate the incidence of hyperkalemic adult CKD patients who were prescribed RAASi and to determine variations in pharmacological interventions to uncover reasons for non-adherence to RAASi treatment. Methods: The incidence of hyperkalemia and non-adherence to RAASi [angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blockers (ARBs)] in CKD patients was examined among 471 patients over the age of 18 years who had estimated-glomerular filtration rate (e-GFR) measurements and were diagnosed with CKD between stages 1 and 5. Hyperkalemia was defined as serum potassium (K+) ≥5 mmol/L. The number of hyperkalemic patients not reaching the target dose, hyperkalemia as a reason for not reaching the target dose, patients receiving sodium polystyrene sulfonate patients discontinuing ACEi/ARBs, having a decreased dose of ACEi/ARBs, or treated with the addition or increasing dose of diuretics were compared between the hyperkalemia groups. Results: Hyperkalemia was detected in 29.1% of the patients (n=137), being mild in 21.7%, moderate in 6.2%, and severe in 1.3%. The main finding was that the frequency of patients not reaching the target dose of ACEi/ARBs treatment due to hyperkalemia, hypotension, or e-GFR increase higher than 30% was dramatically higher among patients having moderate/severe hyperkalemia (p<0.0001). In 12.41% of hyperkalemic patients, hyperkalemia was cited as the cause for not achieving the target dosage of ACEi/ARB therapy. 25.71% of these patients discontinued ACEi/ARBS treatment, 14.29% had decreased dose of this treatment, and 11.43% had increased dose of diuretics or newly prescribed diuretics. However, none of the patients with mild hyperkalemia experienced these events during treatment. Conclusion: These findings suggest that serum K+ concentration may be related to major adverse clinical outcomes and affect the type of pharmacological intervention in CKD, resulting in ACEi-ARB discontinuation and halting to reach the target dose. http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/hyperkalemia-a-cause-of-non-adherence-to-renin--an/63650 chronic kidney diseasehyperkalemiarenin-angiotensin-aldosterone system inhibitors
spellingShingle Sibel Gülçiçek
Nurhan Seyahi
Hyperkalemia: A Cause of Non-adherence to Renin- Angiotensin-Aldosterone System Inhibitors in Chronic Kidney Disease: A Retrospective Study
İstanbul Medical Journal
chronic kidney disease
hyperkalemia
renin-angiotensin-aldosterone system inhibitors
title Hyperkalemia: A Cause of Non-adherence to Renin- Angiotensin-Aldosterone System Inhibitors in Chronic Kidney Disease: A Retrospective Study
title_full Hyperkalemia: A Cause of Non-adherence to Renin- Angiotensin-Aldosterone System Inhibitors in Chronic Kidney Disease: A Retrospective Study
title_fullStr Hyperkalemia: A Cause of Non-adherence to Renin- Angiotensin-Aldosterone System Inhibitors in Chronic Kidney Disease: A Retrospective Study
title_full_unstemmed Hyperkalemia: A Cause of Non-adherence to Renin- Angiotensin-Aldosterone System Inhibitors in Chronic Kidney Disease: A Retrospective Study
title_short Hyperkalemia: A Cause of Non-adherence to Renin- Angiotensin-Aldosterone System Inhibitors in Chronic Kidney Disease: A Retrospective Study
title_sort hyperkalemia a cause of non adherence to renin angiotensin aldosterone system inhibitors in chronic kidney disease a retrospective study
topic chronic kidney disease
hyperkalemia
renin-angiotensin-aldosterone system inhibitors
url http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/hyperkalemia-a-cause-of-non-adherence-to-renin--an/63650
work_keys_str_mv AT sibelgulcicek hyperkalemiaacauseofnonadherencetoreninangiotensinaldosteronesysteminhibitorsinchronickidneydiseasearetrospectivestudy
AT nurhanseyahi hyperkalemiaacauseofnonadherencetoreninangiotensinaldosteronesysteminhibitorsinchronickidneydiseasearetrospectivestudy